Litcius/Paper detail

Engineered nanomedicines block the PD-1/PD-L1 axis for potentiated cancer immunotherapy

Junhao Li, Lujia Huang, Huiling Zhou, Yi-ming Shan, Fangmin Chen, Vesa‐Pekka Lehto, Wujun Xu, Liqiang Luo, Haijun Yu

2022Acta Pharmacologica Sinica43 citationsDOIOpen Access PDF

Topics & Concepts

PD-L1ImmunotherapyMedicineBlockadeCancer immunotherapyCytotoxic T cellImmune checkpointCancer therapyCancerTargeted therapyImmune systemCancer researchCombination therapyImmunologyOncologyPharmacologyInternal medicineBiologyReceptorIn vitroBiochemistryCancer Immunotherapy and BiomarkersNanoplatforms for cancer theranosticsImmune cells in cancer
Engineered nanomedicines block the PD-1/PD-L1 axis for potentiated cancer immunotherapy | Litcius